24 February 2018 - Patent published on novel serotonin 5-HT1A receptor agonists

Neurolixis announced the publication of a new patent on a series of serotonin 5-HT1A receptor agonists. The novel chemical entities (NCEs) are structural analogues of Neurolixis' lead compounds, NLX-112 and NLX-101 which are in clinical development for treatment of dyskinesia in Parkinson's disease and Rett syndrome, respectively. Patent WO/2017/220799 (priority date 24 June 2016) has co-inventors from Neurolixis and from Jagiellonian University, Krakow, as part of a continuing and fruitful drug discovery collaboration.

See the text of the patent on the World Intellectual Property website: WO/2017/220799

25 January 2018 - British charity, Parkinson's UK, awards 1M$ grant to Neurolixis

Neurolixis Inc. has been awarded a 1M$ research grant by the British charity, Parkinson's UK to advance development of NLX-112, a promising Phase 2-ready candidate for treatment of levodopa-induced dyskinesia (LID). NLX-112 is an exceptionally-selective and efficacious serotonin 5-HT1A receptor agonist with considerable potential for treatment of this indication.

Read the full announcement on the Parkinson's UK web site.